Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 4/20 | 0.44 |
| ▸ | KLK1 | P06870 | 3/20 | 0.44 |
| ▸ | MMP3 | P08254 | 8/20 | 0.41 |
| ▸ | MMP2 | P08253 | 9/20 | 0.40 |
| ▸ | CCKBR | P32239 | 5/20 | 0.40 |
| ▸ | MMP9 | P14780 | 2/20 | 0.40 |
| ▸ | MMP8 | P22894 | 2/20 | 0.40 |
| ▸ | MMP14 | P50281 | 2/20 | 0.40 |
| ▸ | CCKAR | P32238 | 3/20 | 0.39 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 6/20 | 0.38 |
| ▸ | MMP7 | P09237 | 6/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5552457 | 1.00 | KLKB1 (0.44) | KLKB1KLK1MMP3MMP2CCKBR | |
| SCHEMBL5556531 | 0.94 | MMP2 (0.43) | KLKB1KLK1MMP3MMP2CCKBR | |
| SCHEMBL5556679 | 0.92 | KLKB1 (0.44) | KLKB1KLK1MMP3MMP2MMP8 | |
| SCHEMBL5557731 | 0.91 | KLKB1 (0.42) | KLKB1KLK1MMP3MMP2MMP9 | |
| SCHEMBL5557724 | 0.84 | KLKB1 (0.36) | KLKB1KLK1MMP3MMP2MMP9 | |
| SCHEMBL5556605 | 0.84 | MMP2 (0.47) | KLKB1KLK1MMP3MMP2MMP1 | |
| SCHEMBL5552925 | 0.84 | MMP3 (0.47) | MMP3MMP2MMP9MMP1 | |
| SCHEMBL5556566 | 0.83 | CTSD (0.39) | KLKB1KLK1MMP3MMP2CCKBR | |
| SCHEMBL5552392 | 0.82 | KLKB1 (0.36) | KLKB1KLK1MMP3MMP2CCKBR | |
| SCHEMBL5557728 | 0.82 | MMP3 (0.35) | KLKB1KLK1MMP3MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | KLKB1 267/4885KLK1 566/4885MMP3 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.